Skip to Content

Press Release

Appointment of Broker

June 7, 2018 at 7:00 AM BST

Released : Jun 07, 2018

RNS Number : 5685Q

Tiziana Life Sciences PLC

07 June 2018


7 June 2018


Tiziana Life Sciences plc

(the "Company" or "Tiziana")


Appointment of Broker



Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, announces that it has appointed Stockdale Securities Limited as its broker, with immediate effect.


Cairn Financial Advisers LLP, who were acting as broker on an interim basis, will cease to act as the Company's broker with immediate effect and will continue to act as the Company's Nominated Adviser.




Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder                               +44 (0)20 7493 2853



Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner                                                          +44 (0)20 7213 0880



Stockdale Securities Limited (Broker)

Andy Crossley/ Antonio Bossi / Owen Matthews                    +44 (0)20 7601 6100




About Tiziana


Tiziana is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered human anti-CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.


For more information go to 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit